Pipeline

Aptadel’s technology is an RNA-based platform for delivery of numerous therapeutic agents targeting tumour cells with improved safety and specificity.

Aptadel's pipeline status

Aptadel’s platform allows the targeting of a wide variety of cancer types. ADEL-001 is an antimetastatic drug of broad indication. ADEL-101 and ADEL-102 are targeting paediatric cancers and ADEL-103 is targeting adult cancers. ADEL-201 is a companion diagnostic kit. Aptadel’s main program is dedicated to fight childhood cancer, in particular Ewing Sarcoma (ES). ES is a rare type of cancerous tumour that grows in bones or soft tissue. It mainly affects children and young people, but is also seen in adults. These tumors are very aggressive, they tend to reappear and develop metastasis after chemotherapy. ES is the second most diagnosed form of primary bone cancer in children and young adults. Due to lack of effective treatments, the survival of patients with pediatric sarcoma that present metastasis at the time of diagnosis is barely 20%.
Program
DISCOVERY
LEAD OPTIMIZATION
PRECLINICAL
CLINICAL
ADEL-001
(Anti-metastatic drug)
ADEL-101
(Ewing Sarcoma)
ADEL-102
(Rhabdomyosarcoma)
ADEL-103
(Adult indication)
ADEL-201
(Diagnostic kit)
ADEL-101 (Ewing Sarcoma) - Preclinic
LEAD OPTIMIZATION
ADEL-102 (Rhabdomyosarcoma) - Preclinic
DISCOVERY
ADEL-103 (Adult indication) - Preclinic
DISCOVERY
ADEL-201 (Diagnostic kit) - Preclinic
DISCOVERY